Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup - Ludwig, Heinz; Dimopoulos, Meletios A; Moreau, Philippe; Chng, Wee-Joo; Goldschmidt, Hartmut; Hájek, Roman; Facon, Thierry; Pour, Ludek; Niesvizky, Ruben; Oriol, Albert; Rosiñol, Laura; Suvorov, Aleksandr; et al. (Leukemia & lymphoma, 2017)
Keywords: Aged; lokální recidiva nádoru; Survival Rate; Antineoplastic Combined Chemotherapy Protocols; mnohočetný myelom; prognóza; protokoly protinádorové kombinované chemoterapie; lidé; senioři; ženské pohlaví; Multiple Myeloma; bortezomib; Dexamethasone; Female; mužské pohlaví; Neoplasm Recurrence, Local; Follow-Up Studies; dexamethason; míra přežití; Humans; oligopeptidy; Oligopeptides; Male; Bortezomib; následné studie; Prognosis